The Cordis tantalum coil stent was assessed in a nonrandomized multicenter trial: 275 patients with stable or unstable angina were entered. Clinical follow-up was for 1 year, with repeat angiography at 6 months. The major adverse cardiac event rates (MACE) were 3%, 14%, and 17% at 1, 7, and 13 months, respectively. The procedural success rate was 96% and the subacute occlusion rate 1.5%, in a group of patients over 60% of whom had ACC/AHA type B2 or C lesions. The binary restenosis rate at 6 months was 17.3%. Minimum lumen diameter increased from 1.07 +/- 0.28 mm preprocedure to 2.93 +/- 0.34 mm poststenting and at 6 months was 1.99 +/- 0.69 mm. These results demonstrate that the Cordis tantalum stent can be used to treat complex lesions with good procedural success and low rates of subacute thrombosis and restenosis at 6 months.

*Stents, Aged, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Angiography, Coronary Disease/*therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Prosthesis Design, Recurrence
dx.doi.org/AID-CCD1060%3E3.0.CO;2-T, hdl.handle.net/1765/4841
Catheterization and Cardiovascular Interventions
Erasmus MC: University Medical Center Rotterdam

Rothman, M, Serruys, P.W.J.C, Grollier, G, Hoorntje, J, van den Bos, A.A, Wijns, W, … Lenderink, T. (2001). Angiographic and clinical one-year follow-up of the Cordis tantalum coil stent in a multicenter international study demonstrating improved restenosis rates when compared to pooled PTCA and BENESTENT-I data: the European Antiplatelet Stent Investigation (EASI). Catheterization and Cardiovascular Interventions, 52(2), 249–259. doi:AID-CCD1060%3E3.0.CO;2-T